Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Figure 1

Kaplan-Meier estimates for (A) brain PFS by hormone receptor (HR) status; (B) PFS by hormone receptor (HR) status; (C) OS by hormone receptor (HR) status; (D) brain PFS by prior capecitabine; (E) PFS by prior capecitabine; and (F) OS by prior capecitabine in patients with brain metastasis on entry.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us